RCUS Long Call Strategy

RCUS (Arcus Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

RCUS (Arcus Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.71B, a beta of 0.81 versus the broader market, a 52-week range of 9.81-31.735, average daily share volume of 1.2M, a public-listing history dating back to 2018, approximately 601 full-time employees. These structural characteristics shape how RCUS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.81 places RCUS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long call on RCUS?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

RCUS snapshot

As of August 14, 2026, spot at $29.41, ATM IV 70.10%, IV rank 39.38%, expected move 20.10%. The long call on RCUS below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long call structure on RCUS specifically: RCUS IV at 70.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 20.10% (roughly $5.91 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RCUS expiries trade a higher absolute premium for lower per-day decay. Position sizing on RCUS should anchor to the underlying notional of $29.41 per share and to the trader's directional view on RCUS stock.

RCUS long call setup

The RCUS long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RCUS at $29.41 on that close, the first option leg uses a $29.41 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RCUS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RCUS shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$29.41N/A

RCUS long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

RCUS long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on RCUS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on RCUS

Long calls on RCUS express a bullish thesis with defined risk; traders use them ahead of RCUS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

RCUS thesis for this long call

The market-implied 1-standard-deviation range for RCUS extends from approximately $23.50 on the downside to $35.32 on the upside. A RCUS long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current RCUS IV rank near 39.38% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on RCUS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RCUS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RCUS-specific events.

RCUS long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RCUS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RCUS alongside the broader basket even when RCUS-specific fundamentals are unchanged. Long-premium structures like a long call on RCUS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RCUS chain quotes before placing a trade.

Frequently asked questions

What is a long call on RCUS?
A long call on RCUS is the long call strategy applied to RCUS (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With RCUS stock at $29.41 on the most recent close, the strikes shown on this page are snapped to the nearest listed RCUS chain strike and the premiums come straight from that session's bid/ask midpoint.
How are RCUS long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the RCUS long call priced from the end-of-day chain at a 30-day expiry (ATM IV 70.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RCUS long call?
The breakeven for the RCUS long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The RCUS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 20.10%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on RCUS?
Long calls on RCUS express a bullish thesis with defined risk; traders use them ahead of RCUS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current RCUS implied volatility affect this long call?
RCUS ATM IV is at 70.10% with IV rank near 39.38%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related RCUS analysis